LivaNova (LIVN) Competitors

LivaNova logo
$92.22 -2.32 (-2.45%)
As of 03:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.

LIVN vs. ZBH, GKOS, BAX, SNN, and PEN

Should you buy LivaNova stock or one of its competitors? LivaNova's main competitors and comparable companies include Zimmer Biomet (ZBH), Glaukos (GKOS), Baxter International (BAX), Smith & Nephew SNATS (SNN), and Penumbra (PEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does LivaNova compare to Zimmer Biomet?

LivaNova (NASDAQ:LIVN) and Zimmer Biomet (NYSE:ZBH) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

LivaNova currently has a consensus price target of $101.22, suggesting a potential upside of 7.07%. Zimmer Biomet has a consensus price target of $114.32, suggesting a potential upside of 10.54%. Given Zimmer Biomet's higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than LivaNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75
Zimmer Biomet
1 Sell rating(s)
15 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.29

LivaNova has a net margin of 13.01% compared to Zimmer Biomet's net margin of 8.95%. LivaNova's return on equity of 16.10% beat Zimmer Biomet's return on equity.

Company Net Margins Return on Equity Return on Assets
LivaNova13.01% 16.10% 7.85%
Zimmer Biomet 8.95%13.02%7.17%

In the previous week, Zimmer Biomet had 10 more articles in the media than LivaNova. MarketBeat recorded 15 mentions for Zimmer Biomet and 5 mentions for LivaNova. Zimmer Biomet's average media sentiment score of 0.50 beat LivaNova's score of 0.15 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LivaNova
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zimmer Biomet
4 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Zimmer Biomet has higher revenue and earnings than LivaNova. Zimmer Biomet is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.39B3.75-$242.47M$3.0031.51
Zimmer Biomet$8.23B2.38$705.20M$3.9526.18

97.6% of LivaNova shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LivaNova has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Summary

LivaNova beats Zimmer Biomet on 9 of the 16 factors compared between the two stocks.

How does LivaNova compare to Glaukos?

Glaukos (NYSE:GKOS) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

99.0% of Glaukos shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

LivaNova has a net margin of 13.01% compared to Glaukos' net margin of -24.60%. LivaNova's return on equity of 16.10% beat Glaukos' return on equity.

Company Net Margins Return on Equity Return on Assets
Glaukos-24.60% -0.97% -0.71%
LivaNova 13.01%16.10%7.85%

In the previous week, Glaukos had 9 more articles in the media than LivaNova. MarketBeat recorded 14 mentions for Glaukos and 5 mentions for LivaNova. Glaukos' average media sentiment score of 0.94 beat LivaNova's score of 0.15 indicating that Glaukos is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Glaukos
6 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LivaNova
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Glaukos has higher earnings, but lower revenue than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Glaukos$507.44M27.13-$187.69M-$2.94N/A
LivaNova$1.39B3.75-$242.47M$3.0031.51

Glaukos presently has a consensus price target of $218.00, suggesting a potential downside of 6.27%. LivaNova has a consensus price target of $101.22, suggesting a potential upside of 7.07%. Given LivaNova's higher probable upside, analysts plainly believe LivaNova is more favorable than Glaukos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Glaukos
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88
LivaNova
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75

Glaukos has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Summary

Glaukos beats LivaNova on 9 of the 16 factors compared between the two stocks.

How does LivaNova compare to Baxter International?

LivaNova (NASDAQ:LIVN) and Baxter International (NYSE:BAX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

LivaNova has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

LivaNova has a net margin of 13.01% compared to Baxter International's net margin of -6.23%. Baxter International's return on equity of 16.23% beat LivaNova's return on equity.

Company Net Margins Return on Equity Return on Assets
LivaNova13.01% 16.10% 7.85%
Baxter International -6.23%16.23%5.08%

97.6% of LivaNova shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 0.2% of Baxter International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, LivaNova had 2 more articles in the media than Baxter International. MarketBeat recorded 5 mentions for LivaNova and 3 mentions for Baxter International. Baxter International's average media sentiment score of 0.75 beat LivaNova's score of 0.15 indicating that Baxter International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LivaNova
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Baxter International
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LivaNova has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.39B3.75-$242.47M$3.0031.51
Baxter International$11.24B1.20-$957M-$1.41N/A

LivaNova presently has a consensus target price of $101.22, indicating a potential upside of 7.07%. Baxter International has a consensus target price of $23.27, indicating a potential downside of 11.03%. Given LivaNova's stronger consensus rating and higher probable upside, analysts clearly believe LivaNova is more favorable than Baxter International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75
Baxter International
3 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86

Summary

LivaNova beats Baxter International on 13 of the 16 factors compared between the two stocks.

How does LivaNova compare to Smith & Nephew SNATS?

LivaNova (NASDAQ:LIVN) and Smith & Nephew SNATS (NYSE:SNN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

LivaNova presently has a consensus price target of $101.22, indicating a potential upside of 7.07%. Smith & Nephew SNATS has a consensus price target of $31.91, indicating a potential upside of 5.19%. Given LivaNova's stronger consensus rating and higher possible upside, research analysts clearly believe LivaNova is more favorable than Smith & Nephew SNATS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75
Smith & Nephew SNATS
2 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.91

LivaNova has a net margin of 13.01% compared to Smith & Nephew SNATS's net margin of 0.00%. LivaNova's return on equity of 16.10% beat Smith & Nephew SNATS's return on equity.

Company Net Margins Return on Equity Return on Assets
LivaNova13.01% 16.10% 7.85%
Smith & Nephew SNATS N/A N/A N/A

In the previous week, LivaNova and LivaNova both had 5 articles in the media. Smith & Nephew SNATS's average media sentiment score of 0.45 beat LivaNova's score of 0.15 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LivaNova
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Smith & Nephew SNATS
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Smith & Nephew SNATS has higher revenue and earnings than LivaNova.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.39B3.75-$242.47M$3.0031.51
Smith & Nephew SNATS$6.30B2.02$625MN/AN/A

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LivaNova has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Summary

LivaNova beats Smith & Nephew SNATS on 9 of the 13 factors compared between the two stocks.

How does LivaNova compare to Penumbra?

LivaNova (NASDAQ:LIVN) and Penumbra (NYSE:PEN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, LivaNova had 2 more articles in the media than Penumbra. MarketBeat recorded 5 mentions for LivaNova and 3 mentions for Penumbra. Penumbra's average media sentiment score of 0.35 beat LivaNova's score of 0.15 indicating that Penumbra is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LivaNova
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Penumbra
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

LivaNova has a net margin of 13.01% compared to Penumbra's net margin of 10.06%. LivaNova's return on equity of 16.10% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
LivaNova13.01% 16.10% 7.85%
Penumbra 10.06%10.39%8.09%

97.6% of LivaNova shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.39B3.75-$242.47M$3.0031.51
Penumbra$1.40B9.00$177.69M$3.9780.70

LivaNova has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market.

LivaNova presently has a consensus price target of $101.22, suggesting a potential upside of 7.07%. Penumbra has a consensus price target of $367.07, suggesting a potential upside of 14.57%. Given Penumbra's higher possible upside, analysts clearly believe Penumbra is more favorable than LivaNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75
Penumbra
0 Sell rating(s)
14 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.18

Summary

Penumbra beats LivaNova on 9 of the 16 factors compared between the two stocks.

Get LivaNova News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIVN vs. The Competition

MetricLivaNovaHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.08B$5.84B$7.47B$11.50B
Dividend YieldN/A1.68%2.47%4.64%
P/E Ratio30.7238.4432.8329.61
Price / Sales3.664.717.935.27
Price / Cash19.0123.3720.8521.62
Price / Book3.704.134.383.66
Net Income-$242.47M$143.14M$3.51B$394.15M
7 Day Performance2.24%-5.08%-5.94%-6.04%
1 Month Performance18.02%-5.40%-6.80%-8.42%
1 Year Performance71.06%-1.10%-2.32%-8.13%

LivaNova Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIVN
LivaNova
2.2918 of 5 stars
$92.22
-2.5%
$101.22
+9.8%
+75.4%$5.08B$1.39B30.723,300
ZBH
Zimmer Biomet
3.7197 of 5 stars
$101.50
-1.7%
$114.32
+12.6%
+16.1%$19.53B$8.57B25.7017,000
GKOS
Glaukos
2.8098 of 5 stars
$245.03
-0.3%
$218.00
-11.0%
+153.8%$14.56B$507.44MN/A1,094
BAX
Baxter International
1.7185 of 5 stars
$25.53
-1.1%
$23.27
-8.8%
+43.9%$13.32B$11.24BN/A37,500
SNN
Smith & Nephew SNATS
1.9127 of 5 stars
$30.99
-0.9%
$31.91
+3.0%
-6.8%$12.98B$6.16BN/A16,988

Related Companies and Tools


This page (NASDAQ:LIVN) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners